Japanese firm Fujitsu has announced the commercial debut of its "Biodrug Design Accelerator," a platform to manage research processes for peptide drug discovery, which many regard as a promising frontier in the field of new drug development. Fujitsu launched the new platform to pharmaceutical companies in Japan on May 18 with plans to expand the offering to the global market in the third quarter of fiscal 2023.

Biodrug Design Accelerator will support peptide drug discovery scientists in pharmaceutical companies to accelerate and improve the efficiency of peptide drug development, specifically through the cycles "design, make, test, analyse" (DMTA), ultimately enabling accelerated and informed design of peptide drug candidates as well as efficient communication among scientists regarding synthesis and testing. The new platform is also compatible with HELM, a method of describing complex biomolecules.

Moving forward, Fujitsu plans to expand the platform's functionality to also support research for nucleic acid drugs and antibody drugs. The development of the platform represents the fruit of ongoing collaboration between Fujitsu and PeptiDream Inc.

PeptiDream offered support in the research and development of the new drug discovery platform as well as in the evaluation of its different functions and operability.